Literature DB >> 11260008

What is the cost of atopic dermatitis in preschool children?

R M Emerson1, H C Williams, B R Allen.   

Abstract

BACKGROUND: Atopic dermatitis (AD) is the most common inflammatory skin disorder and an important cause of morbidity in young children in the U.K. Such disability produces significant economic burden reflected in direct medical costs associated with health service utilization, direct family care costs such as transport costs, indirect costs associated with loss of productivity of carers, and intangible costs associated with the psychological effects of the disease.
OBJECTIVES: In order to evaluate this economic burden we conducted a cross-sectional survey of children aged 1-5 years in the Nottingham area in 1995-96.
METHODS: We sent a postal questionnaire to parents of all children aged 1-5 years with questions to identify those with AD; a second questionnaire was sent to parents of identified children regarding costs and utilization of medical services. Intangible costs were not evaluated.
RESULTS: The 12-month period prevalence of AD according to a dermatologist's diagnosis in 1761 children was 16.5% (95% confidence interval 14.7-18.2%). Total mean disease costs were estimated to be pound79.59 per child over the 12-month period of the study. The most significant costs were due to costs to the state for National Health Service (NHS) consultations ( pound28.62 mean annual cost) and prescriptions ( pound22.03). Consultations with general practitioners accounted for the significant bulk of consultation costs, with only 6% of children being seen in secondary care (17 of 290). Most prescribing costs (76%) were due to emollients and bath preparations. Family care costs ( pound28.94 mean annual cost) accounted for 36% of total disease costs and were associated with changes to the home environment, purchase of over-the-counter medicines, transport costs, visits to homoeopaths and salary loss.
CONCLUSIONS: The results signify that AD is an important cause of economic burden both to the NHS and to the families of affected children. Using population census data and the results in this study, we estimated that the annual U.K. cost of AD in children aged 1-5 years in 1995-96 was pound47 million.

Entities:  

Mesh:

Year:  2001        PMID: 11260008     DOI: 10.1046/j.1365-2133.2001.04077.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  22 in total

Review 1.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 2.  The economics of topical immunomodulators for the treatment of atopic dermatitis.

Authors:  William Abramovits; Mark Boguniewicz; Amy S Paller; Diane L Whitaker-Worth; Mary M Prendergast; Michael Tokar; Kuo B Tong
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Association of staphylococcal superantigen-specific immunoglobulin e with mild and moderate atopic dermatitis.

Authors:  Peck Y Ong; Mona Patel; Ronald M Ferdman; Theresa Dunaway; Joseph A Church
Journal:  J Pediatr       Date:  2008-07-14       Impact factor: 4.406

4.  Oral and Topical Antibiotics for Clinically Infected Eczema in Children: A Pragmatic Randomized Controlled Trial in Ambulatory Care.

Authors:  Nick A Francis; Matthew J Ridd; Emma Thomas-Jones; Christopher C Butler; Kerenza Hood; Victoria Shepherd; Charis A Marwick; Chao Huang; Mirella Longo; Mandy Wootton; Frank Sullivan
Journal:  Ann Fam Med       Date:  2017-03       Impact factor: 5.166

5.  Effects of probiotics on atopic dermatitis: a randomised controlled trial.

Authors:  S Weston; A Halbert; P Richmond; S L Prescott
Journal:  Arch Dis Child       Date:  2005-04-29       Impact factor: 3.791

Review 6.  Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.

Authors:  Darren M Ashcroft; Paul Dimmock; Ruth Garside; Ken Stein; Hywel C Williams
Journal:  BMJ       Date:  2005-02-24

7.  Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema--a long-term analysis from a Swiss perspective.

Authors:  Patricia R Blank; Armin A Blank; Thomas D Szucs
Journal:  BMC Dermatol       Date:  2010-06-25

8.  Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization.

Authors:  Jonathan I Silverberg; Eric L Simpson
Journal:  Pediatr Allergy Immunol       Date:  2013-06-16       Impact factor: 6.377

Review 9.  Topical pimecrolimus: a review of its use in the management of pediatric atopic dermatitis.

Authors:  Lily P H Yang; Monique P Curran
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

10.  Clinical and Economic Burden of Mild-to-Moderate Atopic Dermatitis in the UK: A Propensity-Score-Matched Case-Control Study.

Authors:  Farah Toron; Maureen P Neary; Timothy W Smith; David Gruben; William Romero; Amy Cha; Keyur Patel; Simona Z Vasileva; Mahreen Ameen
Journal:  Dermatol Ther (Heidelb)       Date:  2021-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.